Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study

16 Nov 2016

• By Emily Hayes

Full data from GLAGOV imaging study shows value of driving LDL below 60 mg/dL and presents no red flags for outcomes data due in first quarter of 2017.

The full dataset from Amgen Inc.'s GLAGOV imaging study shows a solid magnitude of plaque regression associated with the PCSK9 inhibitor Repatha and presents no red flags ahead of the release of outcomes data, which are expected in early 2017.

GLAGOV is an intravascular ultrasound study examining the use of a monthly Repatha injection on top of background statin therapy compared with statin therapy alone in 968 patients undergoing coronary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.